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Background 
Psychological distress in rheumatoid arthritis (RA) is significantly higher than the general population 
and impacts disease activity and treatment outcomes. Online interventions have the potential to 
reach large numbers of patients. This study aimed to identify online interventions for psychological 
distress and determine their effectiveness in people with RA and other long-term conditions. 
Methods 
MEDLINE, EMBASE, CINAHL and PsycINFO were searched for studies published between Jan 2007 – 
Jul 2017. Inclusion criteria were randomised controlled trials (RCTs) measuring psychological distress 
in adults. Titles and abstracts were screened independently by two reviewers for relevance and 
design. Methodological quality was assessed by three reviewers using Cochrane Collaboration Risk of 
Bias Tool (differences resolved by discussion). Where information on risk of bias was lacking, authors 
were contacted. Data were extracted independently by four reviewers. Due to clinical heterogeneity 
of studies, a narrative synthesis was conducted. Effectiveness of interventions is reported based on 
between-groups differences in the primary outcomes at the end of study. Cohen’s or Hedge’s effect 
sizes are presented for continuous outcomes and Relative Risk for dichotomous outcomes.  
Results 
The review included 11 RCTs; 2 in people with arthritis, 2 multiple sclerosis, 6 diabetes and 1 irritable 
bowel syndrome; 8 interventions were disease-specific. The methodological quality of most studies 
was poor, mainly due to high attrition rate and selective reporting. Several trials used a wait-list 
control and follow-up was generally short (1-6 months) or not performed in the control group. Table 
1 presents the interventions, outcome measures and evidence of their effectiveness. The most 
common intervention was cognitive behavioural therapy. Some online interventions were guided 
(phone, face-to-face contact to prompt action). Most interventions are not now available. Outcome 
measures varied significantly as the definition of distress used for this review was broad. Of the 11 
interventions 9 were shown to be effective. 
Conclusions 
Although the findings appear to favour online interventions for addressing psychological distress, the 
results are inconclusive due to the overall risk of bias of included studies and insufficient evidence of 
their effectiveness in RA. More disease-specific interventions and good quality RCTs are required in 
people with RA. 
ID Disease Intervention type Primary Outcomes Effectiveness (Effect size* based on between group 
differences) 
Boeschoten 
2017 
Multiple 
sclerosis 
Minder Zorgen  
• disease-specific  
• guided 
Beck Depression Inventory Second 
Edition (BDI-II) 
Not effective (4-month follow-up).  
• BDI-II: Effect size d=0.01; p=0.953 
Bond 2010 Diabetes Diabetes self-
management 
programme 
• disease-specific 
• guided 
Center for Epidemiological Studies 
Depression Scale (CES-D) and Problem 
Areas in Diabetes (PAID) scale 
Effective (6-month follow-up) 
• CES-D: Effect size d= 0.7; p<0.05 
• PAID: Effect size d=0.6; p<0.05 
Cohn 2014 Type 2 diabetes DAHLIA  
• disease-specific  
• unguided 
Center for Epidemiological Studies 
Depression Scale (CES-D), Diabetes 
Distress Scale (DDS) 
Effective (1-week follow-up) 
• CES-D: Effect size d=-0.44; p=0.05 
• Not effective DDS: Effect size not shown 
Ferwerda 
2017 
Rheumatoid 
arthritis 
CBT tailored to 
individual goals and 
characterisitics 
• disease-specific 
• guided 
Beck Depression Inventory (BDI) and 
Impact of Rheumatic Diseases on 
General Health and Lifestyle (IRGL) – 
IRGL-Negative mood & IRGL-Anxiety 
Effective (12-month follow-up) 
• BDI: Effect size d=0.54; p=0.001 
• IRGL-Negative mood: Effect size d=0.38; p=0.01 
• IRGL-Anxiety: Effect size d=0.48; p=0.001 
Fischer 2015 Multiple 
sclerosis 
Deprexis 
• generic 
• unguided 
Beck Depression Inventory – Second 
Edition (BDI-II) 
Effective (9-weeks-follow-up) 
• BDI-II: Effect size d=0.53; p=0.01 
Hunt 2009 Irritable bowel 
syndrome 
CBT for IBS 
• disease-specific 
• guided 
Anxiety Sensitivity Index – GI items 
(ASI-GI) and Anxiety Sensitivity Index – 
non GI items (ASI-non GI) 
Effective (3-month follow-up) 
• ASI-GI: Effect size d=0.63; p<0.01 
• ASI-non GI: Effect size d=0.70; p<0.01 
*Cohen’s d or Hedges g where 0.2 represents small, 0.5 medium and 0.8 large effects. **Relative Risk RR=1 means no difference between groups and its 95%CI crossing 1, 
means the difference is not significant. 
Lorig 2008 Rheumatoid 
arthritis, 
osteoarthritis 
and fibromyalgia 
Arthritis Self-
Management Program 
• generic 
• guided 
Health Distress Scale (HDS) for RA, OA 
and FMS 
Effective (12-month follow-up) 
• HDS-RA: Effect size: d=0.5 (p-value not shown) 
• HDS-OA: Effect size d= 0.4 (p-value not shown) 
• HDS-FMS: Effect size d= 0.03 (p-value not shown)  
Newby 2017 Type 1 and type 
2 diabetes 
Internet generic CBT 
• generic 
• guided 
Patient Health Questionnaire (PHQ-9) 
and Problem Areas In Diabetes (PAID) 
Scale 
Effective (3-month follow-up) 
• PHQ: Effect size g=0.78; p<0.001 
• PAID: Effect size g=0.80;  p=0.01 
Nobis 2015 Type 1 and type 
2 diabetes 
GET.ON Mood Enhancer 
• disease-specific 
• guided 
Center for Epidemiological Studies 
Depression Scale (CES-D) 
Effective (2-month follow-up) 
• CES-D: Effect size d=0.89; p<0.001 
Rondags 
2016 
Type 1 and type 
2 diabetes 
HypoAware 
• disease-specific 
• guided 
Hypoglycaemia Fear Survey (HFS-III) 
 
Not effective (6-month follow-up) 
• Relative Risk (RR)** of reduction in worries  
HFS-II: RR=0.80; 95% CI 0.64 to 1.01; (p=0.059).  
Van 
Bastelaar 
2011 
Type 1 and type 
2 diabetes 
Diabetersgestemd 
• disease-specific 
• guided 
Center for Epidemiological Studies 
Depression Scale (CES-D) 
Effective (1-month follow-up) 
• CES-D: Effect size d=0.70; p<0.001. 
